Yttrium-90-Ibritumomab Tiuxetan and BuCyE High-Dose Chemotherapy Compared with BuCyE Alone As Conditioning Regimen in Patients with B-Cell Non-Hodgkin Lymphoma: IPI Matched Case Control Study At a Single Center

被引：0
|
作者：
Jo, Jae-Cheol
Yoon, Dok Hyun
Kim, Shin
Jang, Seongsoo [2 ]
Park, Chan-Jeoung [2 ]
Chi, Hyun Sook
Park, Chan-Sik [1 ]
Huh, Jooryung [1 ]
Lee, Sang-wook [3 ]
Suh, Cheolwon
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea
[2] Univ Ulsan, Asan Med Ctr, Dept Lab Med, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1581 / 1582
页数：2
相关论文
共 50 条
  • [41] Yttrium-90 ibritumomab tiuxetan (Zevalin®) radioimmunotherapy induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Wiseman, GA
    Witzig, TE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
  • [42] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
    Ciochetto, Chiara
    Botto, Barbara
    Passera, Roberto
    Bello, Marilena
    Benevolo, Giulia
    Boccomini, Carola
    Castellino, Alessia
    Chiappella, Annalisa
    Freilone, Roberto
    Nicolosi, Maura
    Orsucci, Lorella
    Pecoraro, Clara
    Pregno, Patrizia
    Bisi, Gianni
    Vitolo, Umberto
    ANNALS OF HEMATOLOGY, 2018, 97 (09) : 1619 - 1626
  • [43] Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience
    Chiara Ciochetto
    Barbara Botto
    Roberto Passera
    Marilena Bellò
    Giulia Benevolo
    Carola Boccomini
    Alessia Castellino
    Annalisa Chiappella
    Roberto Freilone
    Maura Nicolosi
    Lorella Orsucci
    Clara Pecoraro
    Patrizia Pregno
    Gianni Bisi
    Umberto Vitolo
    Annals of Hematology, 2018, 97 : 1619 - 1626
  • [44] Updated results of high-dose yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHSCT) for poor-risk or refractory B-Cell non-hodgkin's lymphoma.
    Nademanee, Auayporn
    Raubitschek, Andrew
    Molina, Arturo
    Palmer, Joycelynne
    Tsai, Ni-Chun
    Krishnan, Amrita
    Kogut, Neil
    Forman, Stephen
    BLOOD, 2007, 110 (11) : 560A - 560A
  • [45] Induction of complere molecular response with yttrium-90 ibritumomab tiuxetan (zevalin®) in B cell non Hodgkin's lymphoma patients after the achievement of a complete clinical response with chemotherapy regimen
    Orciuolo, E.
    Buda, G.
    Galimberti, S.
    Cecconi, N.
    Boni, G.
    Petrini, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 63 - 63
  • [46] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin®) induces high response rates and durable remissions in patients with relapsed or refractory B-cell non hodgkin's lymphoma (NHL)
    Murray, JL
    Witzig, TE
    Molina, A
    Gordon, L
    Emmanouilides, C
    Vo, K
    Flinn, IW
    Czuczman, M
    Saville, W
    Wiseman, G
    White, CA
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S48 - S49
  • [47] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Yttrium-90-Ibritumomab Tiuxetan (Zevalin) in Combination with a Fludarabine-Based Reduced Conditioning Regimen (RIC) Followed by Allogenic Stem Cell Transplantation for Advanced/Aggressive Non-Hodgkin's Lymphoma (NHL): A Prospective, Multicentre, Open Phase II Study
    Bouabdallah, Krimo
    Furst, Sabine
    Bouabdallah, Reda
    Vigouroux, Stephane
    Tabrizi, Reza
    Melot, Cyril
    Le Gouill, Steven
    Fegueux, Nathalie
    Tournilhac, Olivier
    Mohty, Mohamad
    Blaise, Didier
    Milpied, Noel-Jean
    BLOOD, 2011, 118 (21) : 1304 - 1304
  • [49] Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
    Winter, Jane N.
    Inwards, David J.
    Spies, Stewart
    Wiseman, Gregory
    Patton, David
    Erwin, William
    Rademaker, Alfred W.
    Weitner, Bing Bing
    Williams, Stephanie F.
    Tallman, Martin S.
    Micallef, Ivana
    Mehta, Jayesh
    Singhal, Seema
    Evens, Andrew M.
    Zimmer, Michael
    Molina, Arturo
    White, Christine A.
    Gordon, Leo I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1653 - 1659
  • [50] Evaluation of baseline body-weight dosing of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Wiseman, G
    Conti, P
    Vo, K
    Schilder, RJ
    Foster, P
    Gordon, LI
    Emmanouilides, C
    Silverman, D
    Witzig, TE
    Molina, A
    BLOOD, 2004, 104 (11) : 721A - 721A
12345